

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**208700Orig1s000**

**OTHER REVIEW(S)**

**PMR/PMC DEVELOPMENT TEMPLATE**  
For 506B Reportable<sup>1</sup> PMRs and PMCs only

This form describes and provides the rationale for postmarketing requirements/commitments (PMRs/PMCs) subject to reporting requirements under section 506B of the FDCA.

**Complete this form using the [instructions](#) (see Appendix A) and by referring to [MAPP 6010.9](#), “Procedures and Responsibilities for Developing Postmarketing Commitments and Requirements.”**

**Note: Do *not* use this template for CMC PMCs. Instead, use the CMC PMC Development Template.<sup>1</sup>**

---

**SECTION A: Administrative Information**

**NDA/BLA/Supplement #**      **NDA 208700**  
**PMR/PMC Set (####-#)**      **3326-02**  
**Product Name:**              Lutathera (Lutetium Lu 177 Oxodotreotide)  
**Applicant Name:**            Advanced Accelerator Applications USA, Inc. (AAA)  
**ODE/Division:**                OHOP/DOP2

**SECTION B: PMR/PMC Information**

**1. PMR/PMC Description**

Submit cumulative, integrated safety analyses after 5 and after 10 years of follow-up from an adequate number of patients enrolled in clinical trials to identify and characterize the risks of myelodysplastic syndrome and acute leukemia with Lutathera; include incidence rates, time to onset, predisposing factors and outcomes. These safety evaluations should be adequate to inform labeling of patient populations at highest risk and to provide evidence-based dose modifications and monitoring recommendations.

---

<sup>1</sup> 506B “reportable” includes all studies/trials an applicant has agreed upon or is required to conduct related to clinical safety, clinical efficacy, clinical pharmacology, or nonclinical toxicology (21 CFR 314.81(b)(2)(vii) and 21 CFR 601.70(a)). All PMRs are considered 506 “reportable.” A separate development template is used for 506 B non-reportable (e.g., chemistry, manufacturing, and controls (CMC)) PMCs, which is located in the CST.

---

## 2. PMR/PMC Schedule Milestones<sup>2, 3</sup>

Section 2 is not applicable as no new studies are being requested.

Final Analysis Plan Submission:	June 2018
Interim Safety Report Submission:	September 2021
Final Report Submission:	December 2025

### SECTION C: PMR/PMC Rationale

#### 1. Describe the particular review issue and the goal of the study<sup>4</sup> or clinical trial<sup>5</sup> in the text box below.

[Based on the mode of excretion of LUTATHERA, an increased risks of myelodysplastic syndrome and acute leukemia are suspected. An increased risk of myelodysplastic syndrome, a precursor of acute leukemia was reported in the NETTER-1 trial which supported the approval. However, the proposed follow-up time of 5 years following end of treatment for patients in the NETTER-1 trial is not sufficient to define the magnitude of the risk since onset of this event may not occur for up to 10 years following treatment. Additional follow-up time is required in a defined study population to more precisely estimate the risk and the time to onset of this serisous adverse event.]

#### 2. Explain why this issue can be evaluated post-approval and does not need to be addressed prior to approval. (Select one explanation below.)

- Subpart I or H (animal efficacy rule) PMR: Approved under Subpart I or H (animal efficacy rule) authorities; postmarketing study/trial required to verify and describe clinical benefit [\[Skip to Q.5\]](#)
- Subpart H or E (accelerated approval) PMR: Approved under Subpart H or E (accelerated approval) authorities; postmarketing study/trial required to verify and describe clinical benefit [\[Skip to Q.5\]](#)
- PREA PMR: Meets PREA postmarketing pediatric study requirements [\[Skip to Q.5\]](#)
- FDAAA PMR (safety): Benefit/risk profile of the drug appears favorable; however, there are uncertainties about aspects of the drug's safety profile. Because the investigation will evaluate a serious risk, it meets FDAAA requirements for a postmarketing safety study or trial [\[Go to Q.3\]](#)
- PMC (506B reportable): Benefit/risk profile of the drug appears favorable; however, there are uncertainties about aspects of the drug's efficacy profile or other issues. The purpose of the investigation does not meet requirements under Subpart I/H, H/E, PREA, or FDAAA to be a PMR, and therefore the investigation is a PMC. [\[Go to Q.3\]](#)

#### 3. For FDAAA PMRs and 506B PMCs only

---

<sup>2</sup> Final protocol, study/trial completion, and final report submissions are required milestones. Draft protocol submissions and interim milestones are optional. EXCEPTION: PMRs/PMCs for medical countermeasures may have only draft/final protocol submission dates and no other milestones, since the study/trial will only be initiated in the event of an emergency. Interim milestones may include interim report milestones for studies/trials that may be of long duration. May include interim subject accrual milestone (e.g., for accelerated approval PMRs). Other milestones should be justified in Section D, question 3.

<sup>3</sup> Dates should be numerical (e.g., 05/2016). PREA PMR date format may be MM/DD/YYYY if a day is specified.

<sup>4</sup> A "study" is an investigation that is not a clinical trial, such as an observational (epidemiologic) study, animal study, or laboratory experiment.

<sup>5</sup> A "clinical trial" is any prospective investigation in which the applicant or investigator determines the method of assigning the drug product(s) or other interventions to one or more human subjects. Note that under PREA, clinical trials involving pediatric patients are specifically referred to as "studies."

**The study or trial can be conducted post-approval because:** *[Select all that apply]*

- Longer-term data needed to further characterize the safety/efficacy of the drug
- Based on the purpose and/or design, it is only feasible to conduct the study/trial post-approval
- Prior clinical experience (e.g., with other drugs in the class) indicates adequate safety or efficacy data to support approval, but some uncertainties about safety or efficacy remain and should be further characterized
- Only a small subpopulation is affected (e.g., patients with severe renal impairment) and effects of the drug in the subpopulation can be further evaluated after approval
- Study/trial is to further explore a theoretical concern that does not impact the approval determination
- Other reason (describe in text box below)

4. **For FDAAA PMRs only** *[for PMCs skip to Q.5]. Complete this entire section*

a. **The purpose of the study/clinical trial is to:** *[Select one, then go to Q.4.b]*

- Assess a known serious risk related to the use of the drug
- Assess a signal of serious risk related to the use of the drug
- Identify an unexpected serious risk when available data indicate the potential for a serious risk

*Complete Q4.b if the necessary data can only be obtained through a particular type of nonclinical study or clinical pharmacology trial. Otherwise complete Q4.c and Q4.d.*

b. **FAERS<sup>6</sup> and Sentinel's postmarket ARIA<sup>7</sup> system are not sufficient for the purposes described in Q1. and Q4.a because the safety issue involves:**

*[Select all that apply then to skip to Q.5. If none apply, answer both Q4.c and Q4.d]*

- A serious risk of genotoxicity, carcinogenicity, or reproductive toxicity, and these signals are initially best assessed through in vitro or animal studies.
- A potential drug interaction resulting in lower/higher drug exposure and resultant serious drug risks, and accurate assessment of an interaction is feasible only through in vitro mechanistic studies or clinical pharmacokinetic and pharmacodynamics trials.
- The potential for lower/higher drug exposure and resultant serious drug risks in patients with hepatic or renal impairment, or other metabolic abnormalities, and accurate assessment is feasible only through in vitro mechanistic studies or clinical pharmacokinetic and pharmacodynamics trials.
- An immunologic concern for which accurate assessment requires in vitro development or validation of specific assays.

---

<sup>6</sup> FDA Adverse Event Reporting System (FAERS)

<sup>7</sup> Active Risk Identification and Analysis (ARIA)



Complete Q4.c when FAERS cannot provide the necessary data and Q4.b does not apply

**c. FAERS data cannot be used to fully characterize the serious risk of interest because:**

*[Select all that apply then go to Q.4.d ]*

- Assessment of the serious risk necessitates calculation of the rate of occurrence (e.g., incidence or odds ratio) of the adverse event(s), and FAERS data cannot be used for such a calculation.
- The serious risk of concern has a delayed time to onset, or delayed time to detection after exposure (e.g., cancer), and FAERS data are more useful for detecting events that are closely linked in time to initiation of drug therapy.
- The serious risk of concern occurs commonly in the population (e.g., myocardial infarction) and FAERS data are more useful in detecting rare serious adverse events for which the background rates are low.
- Other

[The desired information needs to come from a clinical trial.]

Complete Q4.d when the ARIA system cannot provide the necessary data and Q4.b does not apply.

**d. The currently available data within the ARIA system cannot be used to fully characterize the serious risk of interest because: *[Select all that apply then go to Q.4.e ]***

- Cannot identify exposure to the drug(s) of interest in the database.
- Serious risk (adverse event) of concern cannot be identified in the database.
- The population(s) of interest cannot be identified in the database.
- Long-term follow-up information required to assess the serious risk are not available in the database.
- Important confounders or covariates are not available or well represented in the database.
- The database does not contain an adequate number of exposed patients to provide sufficient statistical power to analyze the association between the drug and the serious risk of concern.
- The purpose of the evaluation is to rule out a modest relative risk, and observational studies, such as an ARIA analysis, are not well suited for such use.
- Other

The requested information can only be obtained from a clinical trial.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.